Drug class

Alkylating agents clinical trials

A class of medicines: the studies that test any of its 14 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Alkylating Agents.

studies test it: 3,295
open now: 456
in phase 3: 426
first study started: 1990

Get an email when these change. Save the alkylating agents studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Medicines in this class

Studies that test each. A study of two counts under both, and once above.

Cyclophosphamide: 1,537
Temozolomide: 579
Melphalan: 404
Busulfan: 318
Bendamustine: 217
Ifosfamide: 191
Mitomycin: 134
Thiotepa: 131
Carmustine: 85
Dacarbazine: 75
Lomustine: 46
Treosulfan: 40
Chlorambucil: 20
Mechlorethamine: 14

Studies by the year they started

3,263 studies that test it; most in 2009 (164); 12 more planned to start later

Studies that test Alkylating agents, by start year
Year	Studies
1990	6
1991	8
1992	9
1993	13
1994	18
1995	22
1996	37
1997	41
1998	75
1999	74
2000	87
2001	69
2002	83
2003	78
2004	114
2005	134
2006	127
2007	162
2008	131
2009	164
2010	133
2011	115
2012	122
2013	123
2014	127
2015	121
2016	120
2017	121
2018	104
2019	94
2020	98
2021	106
2022	86
2023	96
2024	66
2025	84
2026	95

By phase

A phase 1/2 study counts in both.

Early Phase 1: 66
Phase 1: 966
Phase 2: 2,094
Phase 3: 426
Phase 4: 64
No phase: 153

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Multiple Myeloma: 235
Breast Neoplasms: 209
Glioblastoma: 181
Central Nervous System Neoplasms: 120
Leukemia: 109
Leukemia, Myeloid, Acute: 107
Melanoma: 107
Leukemia, Lymphocytic, Chronic, B-Cell: 100
Precursor Cell Lymphoblastic Leukemia-Lymphoma: 99
Hodgkin Disease: 78
Lymphoma: 78
Lymphoma, Large B-Cell, Diffuse: 68

Who runs them

Industry 290 · Other 3,005

M.D. Anderson Cancer Center (172) · National Cancer Institute (NCI) (134) · Memorial Sloan Kettering Cancer Center (103) · Fred Hutchinson Cancer Center (92) · Children's Oncology Group (86) · City of Hope Medical Center (73) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (68) · Masonic Cancer Center, University of Minnesota (53)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing one of them · 3,295

See all 3,295 studies that test one of the alkylating agents →

Codes

What other systems call Alkylating agents · ClinicalTrials.gg INT006925

MeSH (NLM) D000477Alkylating AgentsOne source ClinicalTrials.gov

System	Code	Name there	Checked by
MeSH (NLM)	D000477	Alkylating Agents	One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.